The DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessAbstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Insulin and insulin resistance.
Wilcox, G. (2005) · PubMed Central · Cited by 2,028
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954 · cited 6×
“T2D is a chronic metabolic complex multifactorial disease, involving many organs, that has become a global pandemic in recent decades.(1,28) T2D is characterised by pancreatic beta-cell dysfunction, increased pancreatic alpha-cell function, and peripheral tissue insulin resistance.”
InfluentialRisk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Huang, S., & Czech, M. P. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.006 · Cited by 1,385
Type 2 Diabetes Mellitus: A Review of Current Trends
Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012) · Oman Medical Journal · doi:10.5001/omj.2012.68 · Cited by 1,338
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Leon, B. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i13.1246 · Cited by 1,215
Goodpaster, B. H. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5755 · Cited by 1,194
Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Epidemiology of type 1 diabetes
Maahs, D. M., West, N. A., Lawrence, J. M., & Mayer-Davis, E. J. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.011 · Cited by 1,092
Makki, K., Froguel, P., & Wolowczuk, I. (2013) · ISRN Inflammation · doi:10.1155/2013/139239 · Cited by 1,085
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Beta Cell Dysfunction and Insulin Resistance
Cerf, M. E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00037 · Cited by 964
Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Self-citationMa, R. C. W., & Chan, J. C. N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12098 · Cited by 827
The current state of diabetes mellitus in India
Kaveeshwar, S. (2014) · Australasian Medical Journal · doi:10.4066/amj.2014.1979 · Cited by 788
Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I. R., Shattock, M., Bottazzo, G. F., & Holman, R. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03062-6 · Cited by 779
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Bariatric Surgery Worldwide 2003
Buchwald, H., & Williams, S. E. (2004) · Obesity Surgery · doi:10.1381/0960892042387057 · Cited by 731
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Bagdade, J. D., Bierman, E. L., & Porte, D. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105646 · Cited by 672
Adiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660
The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus
Ozougwu, O. (2013) · Journal of Physiology and Pathophysiology · doi:10.5897/jpap2013.0001 · Cited by 654
Insulin effects in muscle and adipose tissue
Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70014-6 · Cited by 649
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Prediabetes diagnosis and treatment: A review
Bansal, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.296 · Cited by 579
The medical complications of obesity
Malnick, S. D. H. (2006) · QJM · doi:10.1093/qjmed/hcl085 · Cited by 579
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
What causes the insulin resistance underlying obesity?
Hardy, O. T., Czech, M. P., & Corvera, S. (2012) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283514e13 · Cited by 563
Brethauer, S. A., Aminian, A., Romero-Talamás, H., Batayyah, E., Mackey, J., Kennedy, L., Kashyap, S. R., Kirwan, J. P., Rogula, T., Kroh, M., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182a5034b · Cited by 552
High-fat diets cause insulin resistance despite an increase in muscle mitochondria
Hancock, C. R., Han, D.-H., Chen, M., Terada, S., Yasuda, T., Wright, D. C., & Holloszy, J. O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802057105 · Cited by 538
Nguyen, D. M., & El-Serag, H. B. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.014 · Cited by 531
Excess Lipid Availability Increases Mitochondrial Fatty Acid Oxidative Capacity in Muscle
Turner, N., Bruce, C. R., Beale, S. M., Hoehn, K. L., So, T., Rolph, M. S., & Cooney, G. J. (2007) · Diabetes · doi:10.2337/db07-0093 · Cited by 520
Clark, A., Wells, C. A., BULEY, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J. S., Holman, R. R., & Turner, R. C. (1988) · PubMed · Cited by 518
Bhurosy, T., & Jeewon, R. (2014) · The Scientific World Journal · doi:10.1155/2014/964236 · Cited by 505
Hainer, V., & Aldhoon-Hainerová, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2023 · Cited by 503
Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503
Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
Pancreatic islet plasticity: Interspecies comparison of islet architecture and composition
Steiner, D. J., Kim, A., Miller, K., & Hara, M. (2010) · Islets · doi:10.4161/isl.2.3.11815 · Cited by 494
Mechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Bariatric Surgery: A Review of Procedures and Outcomes
Elder, K. A., & Wolfe, B. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.057 · Cited by 470
Pathogenesis of Type 2 Diabetes Mellitus
Leahy, J. L. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.003 · Cited by 469
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Genetics of Type 2 Diabetes—Pitfalls and Possibilities
Prasad, R., & Groop, L. (2015) · Genes · doi:10.3390/genes6010087 · Cited by 458
Current views on type 2 diabetes
Lin, Y., & Sun, Z. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0260 · Cited by 457
Biarnés, M., Montolio, M., Nacher, V., Raurell, M., Soler, J., & Montanya, E. (2002) · Diabetes · doi:10.2337/diabetes.51.1.66 · Cited by 420
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes
Quesada, I., Tudurí, E., Ripoll, C., & Nadal, Á. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0290 · Cited by 412 · cited 2×
“Hence, it is correct to state that the behaviour of diabetic islet alphacells is different for healthy individuals, as an abundance of nutrients during the postprandial period prevents glucagon secretion in healthy individuals by raising ATP levels (as discussed earlier in this review).(144) Therefore, in T2D, the isl…”
UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation
Vozza, A., Parisi, G., De Leonardis, F., Lasorsa, F. M., Castegna, A., Amorese, D., Marmo, R., Calcagnile, V. M., Palmieri, L., Ricquier, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317400111 · Cited by 407
Endocrine disruptors in the etiology of type 2 diabetes mellitus
Alonso-Magdalena, P., Quesada, I., & Nadal, A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.56 · Cited by 404
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Cellular composition of the human diabetic pancreas
Rahier, J., Goebbels, R. M., & Henquin, J. C. (1983) · Diabetologia · doi:10.1007/bf00251826 · Cited by 395
Genetic Liability of Type 1 Diabetes and the Onset Age Among 22,650 Young Finnish Twin Pairs
Hyttinen, V., Kaprio, J., Kinnunen, L., Koskenvuo, M., & Tuomilehto, J. (2003) · Diabetes · doi:10.2337/diabetes.52.4.1052 · Cited by 394
The current state of diabetes mellitus in India.
Kaveeshwar, S. A., & Cornwall, J. (2014) · PubMed · doi:10.4066/amj.2013.1979 · Cited by 393 · cited 1×
“urban areas of South India, almost 20% of the population was estimated to be affected by diabetes in 2008.(65) In 2014, a study revealed that 46% of newly”
Goodpaster, B. H., Katsiaras, A., & Kelley, D. E. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2191 · Cited by 390
Wang, Z., & Thurmond, D. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.034355 · Cited by 386
Nguyen, N. T., Nguyen, X.-M. T., Lane, J., & Wang, P. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0335-4 · Cited by 385
Glucolipotoxicity of the pancreatic beta cell
Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D., & Fontés, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.08.006 · Cited by 382
Diabetic Neuropathy: An intensive review
Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., & Rasmussen, K. A. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.2.160 · Cited by 382
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
Type 2 diabetes mellitus in children and adolescents
Reinehr, T. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.270 · Cited by 363
Mozaffarian, D., Kamineni, A., Carnethon, M., Djoussé, L., Mukamal, K. J., & Siscovick, D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.21 · Cited by 358
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause
Taylor, R. (2008) · Diabetologia · doi:10.1007/s00125-008-1116-7 · Cited by 352
Ali, O. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i4.114 · Cited by 350
Saliba, W., Nitzan, O., Chazan, B., & Elias, M. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s51792 · Cited by 345
Chan, C. B., De Leo, D., Joseph, J. W., McQuaid, T. S., Ha, X. F., Xu, F., Tsushima, R. G., Pennefather, P. S., Salapatek, A. M. F., & Wheeler, M. B. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1302 · Cited by 341
Noble, J. A., & Erlich, H. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007732 · Cited by 335
Parathyroid hormone: past and present
Potts, J. T. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06057 · Cited by 327
REAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326
Perry, B. D., Caldow, M. K., Brennan‐Speranza, T. C., Sbaraglia, M., Jerums, G., GARNHAM, A. P., Wong, C. Y., Levinger, P., Haq, M. A. U., Hare, D. L., et al. (2016) · PubMed · Cited by 318
Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo
Kawamori, D., Kurpad, A. J., Hu, J., Liew, C. W., Shih, J. L., Ford, E. L., Herrera, P. L., Polonsky, K. S., McGuinness, O. P., & Kulkarni, R. N. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.007 · Cited by 316
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Prevalence of nutrient deficiencies in bariatric patients
Toh, S. Y., Zarshenas, N., & Jorgensen, J. (2009) · Nutrition · doi:10.1016/j.nut.2009.03.012 · Cited by 315
Type 2 Diabetes in Youth: Epidemiology and Pathophysiology
D’Adamo, E., & Caprio, S. (2011) · Diabetes Care · doi:10.2337/dc11-s212 · Cited by 315
Standards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
The Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314
Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus
Moreno-Indias, I., Cardona, F., Tinahones, F. J., & Queipo-Ortuño, M. I. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00190 · Cited by 310
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
Type 2 Diabetes Mellitus and Hypertension
Lastra, G., Syed, S., Kurukulasuriya, L. R., Manrique, C., & Sowers, J. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.005 · Cited by 307
Relationships between plasma measures of oxidative stress and metabolic control in NIDDM
Nourooz-Zadeh, J., Rahimi, A., Tajaddini-Sarmadi, J., Tritschler, H., Rosen, P., Halliwell, B., & Betteridge, D. J. (1997) · Diabetologia · doi:10.1007/s001250050729 · Cited by 303
Link between obesity and type 2 diabetes
Golay, A., & Ybarra, J. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.010 · Cited by 301
Type 2 Diabetes Mellitus, Pandemic in 21st Century
Ginter, E., & Simko, V. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5441-0_6 · Cited by 299
The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids
Dokken, B. B. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.3.160 · Cited by 299
Burke, J. P., Williams, K., Gaskill, S. P., Hazuda, H. P., Haffner, S. M., & Stern, M. P. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.13.1450 · Cited by 294
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Follow-up of Nutritional and Metabolic Problems After Bariatric Surgery
Fujioka, K. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.481 · Cited by 260
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose
Brereton, M. F., Iberl, M., Shimomura, K., Zhang, Q., Adriaenssens, A. E., Proks, P., Spiliotis, I. I., Dace, W., Mattis, K. K., Ramracheya, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5639 · Cited by 259
Stress and Type 2 Diabetes: A Review of How Stress Contributes to the Development of Type 2 Diabetes
Kelly, S. J., & Ismail, M. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122921 · Cited by 256
Epidemiology of and risk factors for type 2 diabetes in Egypt
Hegazi, R., El-Gamal, M., Abdel-Hady, N., & Hamdy, O. (2016) · Annals of Global Health · doi:10.1016/j.aogh.2015.12.011 · Cited by 254
Aroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Prediabetes and Lifestyle Modification: Time to Prevent a Preventable Disease
Tuso, P. (2014) · The Permanente Journal · doi:10.7812/tpp/14-002 · Cited by 252
Hyperglucagonemia and Blood Glucose Regulation in Normal, Obese and Diabetic Subjects
Sherwin, R. S., Fisher, M., Hendler, R., & Felig, P. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602262940901 · Cited by 252
Chan, C. B., MacDonald, P. E., Saleh, M. C., Johns, D. C., Marbàn, E., & Wheeler, M. B. (1999) · Diabetes · doi:10.2337/diabetes.48.7.1482 · Cited by 242
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., et al. (2017) · Nature · doi:10.1038/nature22378 · Cited by 241
van Loon, L. J. C., Koopman, R., Manders, R., van der Weegen, W., van Kranenburg, G. P., & Keizer, H. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00464.2003 · Cited by 239
The role of dysregulated glucagon secretion in type 2 diabetes
D'Alessio, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01449.x · Cited by 238
Small-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Gastrointestinal complications of diabetes mellitus
Krishnan, B. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i3.51 · Cited by 226
Variation in the recorded incidence of amputation of the lower limb in England
Holman, N., Young, R. J., & Jeffcoate, W. J. (2012) · Diabetologia · doi:10.1007/s00125-012-2468-6 · Cited by 226
Management of adult diabetic ketoacidosis
Gosmanov, A. R., Gosmanova, E., & Dillard-Cannon, E. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s50516 · Cited by 223
Pathogenesis of diabetic nephropathy
Cao, Z., & Cooper, M. E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00131.x · Cited by 219
Dobnig, H., Piswanger-Sölkner, J. C., Roth, M., Obermayer-Pietsch, B., Tiran, A., Strele, A., Maier, E., Maritschnegg, P., Sieberer, C., & Fahrleitner-Pammer, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0460 · Cited by 217
Adipose tissue and the insulin resistance syndrome
Frayn, K. N. (2001) · Proceedings of the Nutrition Society · doi:10.1079/pns200195 · Cited by 217
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Doehner, W., Erdmann, E., Cairns, R., Clark, A. L., Dormandy, J. A., Ferrannini, E., & Anker, S. D. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.039 · Cited by 215
Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Brereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
UCP2 and UCP3 in muscle controlling body metabolism
Schrauwen, P., & Hesselink, M. (2002) · Journal of Experimental Biology · doi:10.1242/jeb.205.15.2275 · Cited by 205
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
Costanzo, P., Cleland, J. G. F., Pellicori, P., Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J., & Atkin, S. L. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1551 · Cited by 199
Fatty liver disease in diabetes mellitus.
Bhatt, H. B., & Smith, R. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3881.2015.01.03 · Cited by 199
Type 2 Diabetes Mellitus and Skeletal Muscle Metabolic Function
Phielix, E., & Mensink, M. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.01.020 · Cited by 198
Brain glucose sensing and neural regulation of insulin and glucagon secretion
Thorens, B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01453.x · Cited by 198
Apoptosis in pancreatic β-islet cells in Type 2 diabetes
Tomita, T. (2016) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2016.919 · Cited by 197
A look inside the diabetic brain: Contributors to diabetes-induced brain aging
Wrighten, S. A., Piroli, G. G., Grillo, C. A., & Reagan, L. P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.013 · Cited by 195
Micronutrient deficiencies after gastric bypass for morbid obesity.
Jd, H. (1986) · PubMed · Cited by 194
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Marsico, F., Paolillo, S., Gargiulo, P., Bruzzese, D., Dell’Aversana, S., Esposito, I., Renga, F., Esposito, L., Marciano, C., Dellegrottaglie, S., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa082 · Cited by 191
Nitric oxide and vascular insulin resistance
Wu, G., & Meininger, C. J. (2009) · BioFactors · doi:10.1002/biof.3 · Cited by 190
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190
Autonomic Neuropathy in Diabetes Mellitus
Verrotti, A., Prezioso, G., Scattoni, R., & Chiarelli, F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00205 · Cited by 187
Henquin, J.-C. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70010-9 · Cited by 183
Karalliedde, J., & Gnudi, L. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu405 · Cited by 183 · cited 1×
“ciency, treatment requirements and prognosis varies between patients.(38,39) Although treatments are available, diabetes remains a leading cause of blindness, end-stage renal disease, lower limb amputation and cardiovascular disease.”
Madeira, F. B., Silva, A. A., Veloso, H. F., Goldani, M. Z., Kac, G., Cardoso, V. C., Bettiol, H., & Barbieri, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060673 · Cited by 181
Blaak, E. E., van Aggel-Leijssen, D. P., Wagenmakers, A. J., Saris, W. H., & van Baak, M. A. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2102 · Cited by 178
Lean diabetes mellitus: An emerging entity in the era of obesity
George, A. M., Jacob, A. G., & Fogelfeld, L. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.613 · Cited by 177
Gender aspects in type 2 diabetes mellitus and cardiometabolic risk
Sattar, N. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.006 · Cited by 177
Mason, T. M., Goh, T., Tchipashvili, V, Sandhu, H., Gupta, N., Lewis, G. F., & Giacca, A. (1999) · Diabetes · doi:10.2337/diabetes.48.3.524 · Cited by 177
Human IAPP–induced pancreatic β cell toxicity and its regulation by autophagy
Shigihara, N., Fukunaka, A., Hara, A., Komiya, K., Honda, A., Uchida, T., Abe, H., Toyofuku, Y., Tamaki, M., Ogihara, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69866 · Cited by 177
Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes
Funk, S. D., Yurdagul, A., & Orr, A. W. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/569654 · Cited by 176
Skin disorders in diabetes mellitus: an epidemiology and physiopathology review
de Macedo, G. M. C., Nunes, S., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0176-y · Cited by 176
Clinical review: Ketones and brain injury
White, H., & Venkatesh, B. (2011) · Critical Care · doi:10.1186/cc10020 · Cited by 175
Glutathionylation Acts as a Control Switch for Uncoupling Proteins UCP2 and UCP3
Mailloux, R. J., Seifert, E. L., Bouillaud, F., Aguer, C., Collins, S., & Harper, M.-E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240242 · Cited by 174
Prevalence and complications of diabetes mellitus in Northern Africa, a systematic review
Bos, M., & Agyemang, C. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-387 · Cited by 172
A causal role for hyperinsulinemia in obesity
Templeman, N. M., Skovsø, S., Page, M. M., Lim, G. E., & Johnson, J. D. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0449 · Cited by 168
The role of bariatric surgery to treat diabetes: current challenges and perspectives
Koliaki, C., Liatis, S., le Roux, C. W., & Kokkinos, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0202-6 · Cited by 167
Ahlqvist, E., Ahluwalia, T. S., & Groop, L. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.157016 · Cited by 166
Wang, C.-S., Wang, S.-T., Yao, W.-J., Chang, T.-T., & Chou, P. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm061 · Cited by 166
The Spectrum of Diabetic Neuropathies
Tracy, J. A., & Dyck, P. J. B. (2008) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2007.10.010 · Cited by 164
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163
Liao, C., Zhang, D., Mungo, C., Andrew Tompkins, D., & Zeidan, A. M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.095 · Cited by 162
Ardisson Korat, A. V., Willett, W. C., & Hu, F. B. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0103-5 · Cited by 162
Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers
Xiao, Y., Tang, Z., Wang, J., Liu, C., Kong, N., Farokhzad, O. C., & Tao, W. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008879 · Cited by 162
D’Addio, F., Valderrama Vasquez, A., Ben Nasr, M., Franek, E., Zhu, D., Li, L., Ning, G., Snarski, E., & Fiorina, P. (2014) · Diabetes · doi:10.2337/db14-0295 · Cited by 160
Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes.
Pietropaolo, M., Barinas-Mitchell, E., Pietropaolo, S. L., Kuller, L. H., & Trucco, M. (2000) · Diabetes · doi:10.2337/diabetes.49.1.32 · Cited by 159
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Toll-like receptors regulate B cell cytokine production in patients with diabetes
Jagannathan, M., McDonnell, M., Liang, Y., Hasturk, H., Hetzel, J., Rubin, D., Kantarci, A., Van Dyke, T. E., Ganley-Leal, L. M., & Nikolajczyk, B. S. (2010) · Diabetologia · doi:10.1007/s00125-010-1730-z · Cited by 156
Islet Amyloid Polypeptide (IAPP) Transgenic Rodents as Models for Type 2 Diabetes
Matveyenko, A. V., & Butler, P. C. (2006) · ILAR Journal · doi:10.1093/ilar.47.3.225 · Cited by 150
Nutritional status seven years after Roux-en-Y gastric bypass surgery.
Avinoah, E., Ovnat, A., & CHARUZI, I. (1992) · PubMed · Cited by 148
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
El-Badawy, A., & El‐Badri, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151938 · Cited by 147
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143
Neural regulation of pancreatic islet cell mass and function
Thorens, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12346 · Cited by 140
Diabetes: Have We Got It All Wrong?
Corkey, B. E. (2012) · Diabetes Care · doi:10.2337/dc12-0825 · Cited by 140
Mitochondrial proticity and ROS signaling: lessons from the uncoupling proteins
Mailloux, R. J., & Harper, M. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.004 · Cited by 139
Robson-Doucette, C. A., Sultan, S., Allister, E. M., Wikstrom, J. D., Koshkin, V., Bhattacharjee, A., Prentice, K. J., Sereda, S. B., Shirihai, O. S., & Wheeler, M. B. (2011) · Diabetes · doi:10.2337/db11-0132 · Cited by 136
Reaven, G. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.017 · Cited by 135
Secondary Hyperparathyroidism: Pathophysiology and Treatment
Saliba, W., & El-Haddad, B. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.05.090026 · Cited by 133
Galgani, J. E., Heilbronn, L. K., Azuma, K., Kelley, D. E., Albu, J. B., Pi-Sunyer, X., Smith, S. R., Ravussin, E., & and the Look AHEAD Adipose Research Group (2008) · Diabetes · doi:10.2337/db08-0043 · Cited by 133
Altered Islet Composition and Disproportionate Loss of Large Islets in Patients with Type 2 Diabetes
Kilimnik, G., Zhao, B., Jo, J., Periwal, V., Witkowski, P., Misawa, R., & Hara, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027445 · Cited by 132
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase
Ćorković, I., Gašo-Sokač, D., Pichler, A., Šimunović, J., & Kopjar, M. (2022) · Life · doi:10.3390/life12111692 · Cited by 208
“Various socioeconomic and cultural aspects cause overweight and obesity, which are consequently leading to increased risk for the disease’s development [1,2].”
BackgroundSingh, A., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive Physiology · doi:10.1002/cph4.70003 · Cited by 163
Anh, N. H., Mai, Q. D., Dinh, N. X., Huy, T. Q., Tri, D. Q., Loan, L. T. N., Bui, H. V., & Le, A.-T. (2022) · RSC Advances · doi:10.1039/d1ra08311b · Cited by 100
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.